Skip to main content Skip to search Skip to main navigation

FDA: Guidance on Computer Software Assurance (CSA)

On September 24, 2025, the FDA published its long-awaited final guidance “Computer Software Assurance for Production and Quality System Software” for medical devices. The document supersedes Section 6 of the FDA’s earlier document, “General Principles of Software Validation,” introducing a modern, risk-based framework that emphasizes intended use, process risk, and patient safety. 

Purpose of the Guidance 

The CSA guidance aims to reduce unnecessary validation burden, foster adoption of digital technologies (including cloud-based tools), and prepare industry for the alignment of FDA’s Quality System Regulation (21 CFR Part 820) with ISO 13485:2016 in February 2026. 

Key Takeaways for Manufacturers 

  • Risk-based approach: Scale assurance activities to software’s intended use and process risk 
  • Intended use: Validation of software that is used as part of production or quality system for its intended use – including cloud computing models 
  • Flexible testing: Risk based use of scripted and exploratory methods 
  • Vendor oversight: Stronger reliance on supplier assessments, audits, and certifications 
  • Smarter documentation: FDA recommends incorporating the use of digital records, such as system logs, audit trails, and other data generated and maintained by the software. 
  • ISO Transition: Build CSA into QMS now to ensure readiness for 2026 harmonisation


Source:

FDA:FDA Guidance Documents - Computer Software Assurance for Production and Quality System Software

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may Also be Interested in the Following Articles

FDA Findings: Safe Aseptic Manufacturing Starts With Facility Design

FDA Findings: Safe Aseptic Manufacturing Starts With Facility Design

At the PDA/FDA Joint Regulatory Conference 2026, FDA made it clear that modern equipment alone does not ensure sterility assurance. The article examines GMP deficiencies identified during FDA inspections and the role of facility design in aseptic manufacturing.

Read more
Question of the Week | GMP-Verlag

How is Qualification Carried out in Accordance With the V-model Described in GAMP® 5?

Here's the answer:
Read more
News: Medical Devices

EMA: Harmonisation of Combination-Product Quality Assessment

EMA’s Combination Products Operational Group (COMBO) is working to improve alignment between notified body opinions (NBOps) and pharmaceutical quality assessment, according to its report on the meeting held on 8 October 2026.
Read more
PIC/S: Revision of the Framework for International Cooperation

PIC/S: Revision of the Framework for International Cooperation

PIC/S has revised the framework governing its international cooperation. The updated Pharmaceutical Inspection Co-operation Scheme, PIC/S 1/95 (Rev. 7), was adopted in Istanbul on 2 November 2026 and entered into force on the same day.
Read more
FDA Updates Framework for Coordinating Facility Evaluations and Inspections

FDA Updates Framework for Coordinating Facility Evaluations and Inspections

FDA has revised its framework for collaboration between the Center for Drug Evaluation and Research (CDER) and the Office of Inspections and Investigations (OII). Version 2.0 of the Concept of Operations (ConOps), effective October 21, 2026, supersedes the original June 2017 version.
Read more
Outsourced Activities in the GDP Environment Part III: Contract Giver and Contract Acceptor

Outsourced Activities in the GDP Environment Part III: Contract Giver and Contract Acceptor

For any outsourced GDP activity, there is a need for delimitation of responsibilities between a client (contract giver) and a contractor (contract acceptor). Read more about their roles and responsibilities in the following excerpt from GMP:KnowHow Pharmalogistics (GDP).

Read more
Previous
Next